Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Accurate 3D recording: Integrating ground-based LiDAR data and 3D segmentation network to extract 3D traits and analyze genetics in wheat populations.

Plant phenomics (Washington, D.C.)·2026
Same author

Combining RGB imaging with a two-stage deep learning method to reveal genetic variation of wheat sprouting traits.

Plant phenomics (Washington, D.C.)·2026
Same author

Systematic multi-component profiling of Xiangju Rupining Capsule via online comprehensive two-dimensional liquid chromatography-quadrupole time-of-flight mass spectrometry coupled with stepwise acquisition workflow and multivariate data mining.

Journal of chromatography. A·2026
Same author

Amphiphilic Ebselen Conjugate Suppresses Tripartite Motif-Containing 21-Glutathione Peroxidase 4 Axis-Dependent Neuronal Ferroptosis and Ameliorates Epilepsy.

ACS nano·2026
Same author

Ferroptosis-associated transcriptional factors in neurological diseases: molecular mechanisms and therapeutic prospects.

Experimental & molecular medicine·2025
Same author

Hepatocellular carcinoma with microvascular invasion: from theory to clinical practice.

Science China. Life sciences·2025
Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026
Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026
Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026
Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026
Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

MDR1 C2005T polymorphism changes substrate specificity.

Lijuan Liu1, Lan Fan, Xiangdong Peng

  • 1Institute of Clinical Pharmacology, Central South University, Changsha, China.

Cancer Chemotherapy and Pharmacology
|March 24, 2010
PubMed
Summary
This summary is machine-generated.

The MDR1 C2005T polymorphism impacts how cells transport substances and respond to certain chemotherapy drugs. This genetic variation may affect drug effectiveness and how the body processes P-glycoprotein substrates.

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Related Experiment Videos

Last Updated: Jun 14, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Area of Science:

  • Pharmacogenomics
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • The MDR1 gene encodes P-glycoprotein (P-gp), a crucial efflux transporter involved in drug resistance.
  • Genetic variations, such as the MDR1 C2005T polymorphism, can potentially alter P-gp function and influence treatment outcomes.

Purpose of the Study:

  • To investigate the functional consequences of the MDR1 C2005T polymorphism on P-gp efflux activity.
  • To determine the effect of this polymorphism on cellular sensitivity to various anticancer agents.

Main Methods:

  • Quantitative real-time PCR and immunoblotting were used to measure MDR1 mRNA and protein expression.
  • Confocal microscopy assessed P-glycoprotein localization.
  • Cell cytotoxicity assays (MTT) and Rh123 permeability assays evaluated drug sensitivity and efflux activity.

Main Results:

  • The MDR1 C2005T polymorphism did not alter MDR1 expression levels or P-gp plasma membrane trafficking.
  • Cells with the MDR1 C2005T polymorphism showed altered sensitivity to paclitaxel and etoposide.
  • A significant increase in Rhodamine 123 (Rh123) efflux transport was observed in cells with the MDR1 C2005T polymorphism.

Conclusions:

  • The MDR1 C2005T polymorphism modifies the transepithelial permeability of P-gp substrates like Rh123.
  • This genetic variation influences cellular response to specific cytotoxic drugs, potentially impacting drug disposition and therapeutic efficacy.